Skip to navigation Skip to content

News release

Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding

May 1, 2025

Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, yesterday announced a grant through the Apotex Global Health Access Fund to the Foundation for Mother and Child Health ("FMCH") in Mumbai, India to support programs that promote maternal health and address child malnutrition.

Building on Apotex's legacy of giving, including Apotex's global medicine donation program, the Apotex Global Health Access Fund focuses on addressing unequal access to care and low health literacy within communities where there are poor social determinants of health. Apotex's Indian headquarters are in Bangalore.

FMCH is the latest Apotex Global Health Access Fund grant recipient, and the first in India. The organization will receive CAD $100,000 annually over the next three years to support the 1000 Days Intervention project, which provides comprehensive maternal health services to high-risk pregnant women in Thane, aiming to reduce malnutrition and improve maternal health outcomes.

"We are thrilled to announce this grant to the Foundation for Mother and Child Health, which underscores our commitment to addressing health disparities," said Ariel Alon, Chief Operation Officer at Apotex. "By supporting initiatives like the 1000 Days Intervention project, we aim to make a significant impact on maternal health and the well-being of families, supporting people on their health journeys."

"We're delighted to partner with Apotex to bring FMCH's 1000 Days Intervention program to Thane," said FMCH Development Lead Mrunal Patil. "This 3-year collaboration marks a powerful step toward our shared vision of reducing preventable malnutrition. With Apotex's support, we'll be able to reach hundreds of families with our program Poshan during the most critical window of a child’s life. We’re deeply grateful for their commitment to community health and excited for the journey ahead."

In its inaugural year, the Apotex Global Health Access Fund focuses on funding maternal health programs in Canada, the United States, India, and Mexico with an annual budget of $1 million. The first grant recipient was the Rexdale Community Health Centre in Toronto. This was followed by Healthy Mothers, Healthy Babies Coalition of Broward County (HMHB/Broward) in Lauderhill, Florida, receiving $242,000 annually over three years to support their Mahogany Project, and Vida y Familia México, I.A.P. (VIFAC) in Mexico, receiving $100,000 annually over three years to support their comprehensive maternal and child health services.

For more information about Foundation for Mother and Child Health, please visit FMCH India.

 

About Apotex

Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at www.apotex.com.

Media Contact: [email protected]

Media inquries

Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.

Contact our media team

Latest news

  • Oct 9, 2026

    Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026

    TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.

  • Oct 5, 2026

    Apotex Health Corp. announces closing of $1,250 million inaugural senior unsecured notes offering

    Toronto, Ontario, October 5, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today the closing of the previously announced offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Offering was made through a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.

  • Sep 29, 2026

    Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering

    Toronto, Ontario, September 28, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today that it has priced a private placement offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Notes are being offered on an agency basis by a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.